Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Narjis Fatima, BSMedTech,MPhil, Richard Christopherson, PhDEmeritus Professor, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc

Blood (2019) 134 (Supplement_1): 5443.

https://doi.org/10.1182/blood-2019-130082

Published: 2019

Journal Articles

TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status

Narjis Fatima, BSMedTech,MPhil, Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Edwin Iwanowicz, PhD, Richard Christopherson, PhDEmeritus Professor, Giles Best, BSc, PhD, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS

Blood (2019) 134 (Supplement_1): 1735.

https://doi.org/10.1182/blood-2019-132160

Published: 2019

Journal Articles

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

Kyle R Crassini, MBBS, BSc, Yandong Shen, BMedSc (Hon), William S. Stevenson, MBBS, PhD, Stephen P. Mulligan, PhD, FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc, Richard Christopherson, PhD Emeritus Professor

Blood (2018) 132 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2018-99-118264

Published: 2018

Journal Articles

ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment

Narjis Rizwan, BSMedTech, MPhil, PhD, Yandong Shen, BMedSc (Hon), Edwin Iwanowicz, PhD, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Kyle R Crassini, MBBS, BSc, Richard Christopherson, PhD Emeritus Professor, Oliver Giles Best, PhD BSc

Blood (2018) 132 (Supplement 1): 3145.

https://doi.org/10.1182/blood-2018-99-115555

Published: 2018

Journal Articles

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Yandong Shen, BMedSc (Hon), Kyle R Crassini, MBBS, BSc, Michael E O'Dwyer, MD, Michael Francis O'Neill, PhD BA, Richard Christopherson, PhD Emeritus Professor, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc

Blood (2018) 132 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2018-99-115574

Published: 2018

Journal Articles

Inhibition of AKT By MK2206 but Not PI3-Kinase δ By Idelalisib Is Effective Against CLL Cells in an In Vitro Model of the Hypoxic Microenvironment

Yandong Shen, BMedSc (Hon), Kyle R Crassini, MBBS,BE,BSc, Stephen Mulligan, PhDFRACP,FRCPA,MBBS, Richard Christopherson, PhDEmeritus Professor, Oliver Giles Best, PhDBSc

Blood (2017) 130 (Supplement 1): 5340.

https://doi.org/10.1182/blood.V130.Suppl_1.5340.5340

Published: 2017

Journal Articles

Analysis of mRNA Expression in Peripheral, Bone Marrow and Lymph Node Dervied CLL Cells Using the Nanosting Ncounter Platform

Kyle R Crassini, MBBS,BE,BSc, Yandong Shen, BMedSc (Hon), Richard Christopherson, PhDEmeritus Professor, William S. Stevenson, MBBS,PhD, Stephen Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc

Blood (2017) 130 (Supplement 1): 4279.

https://doi.org/10.1182/blood.V130.Suppl_1.4279.4279

Published: 2017

NARROW

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Inhibition of AKT By MK2206 but Not PI3-Kinase δ By Idelalisib Is Effective Against CLL Cells in an In Vitro Model of the Hypoxic Microenvironment

Analysis of mRNA Expression in Peripheral, Bone Marrow and Lymph Node Dervied CLL Cells Using the Nanosting Ncounter Platform

Email alerts

ASH Publications

American Society of Hematology

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Inhibition of AKT By MK2206 but Not PI3-Kinase δ By Idelalisib Is Effective Against CLL Cells in an In Vitro Model of the Hypoxic Microenvironment

Analysis of mRNA Expression in Peripheral, Bone Marrow and Lymph Node Dervied CLL Cells Using the Nanosting Ncounter Platform

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only